Nuevolution published their Q3 report this morning (FY Jul 1 - Jun 30). Net sales amounted to SEK 1.6 (6.0) million and operating costs was SEK -31.4 (-27.6) million, giving an EBIT of SEK -29.8 (-21.7) million. Net result for the period was SEK -29.0 (-20.9) million. The start of the year has seen progress across the board and the company seem to be well on track to expand their business. Of particular interest is the developments in the Almirall and Amgen collaborations, as well as the internal BET-inhibitor program, which all seem to progress according to plan.